SCYNEXIS, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
SCYNEXIS, Inc. (SCYX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $4.70 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-13.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2017-03-13
- SCYNEXIS, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2014-09-30 was $0.00.
- SCYNEXIS, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2014-06-30 was $0.00.
- SCYNEXIS, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2014-03-31 was $544.00K.
- SCYNEXIS, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2016 was $4.70M.
- SCYNEXIS, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2014 was $544.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month |
|---|---|---|---|---|
| 2016-12-31 | $4.70M 10-K · filed 2017-03-13 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-07 | $0.00 derived: sum of 2 quarters · filed 2016-03-07 | $0.00 derived: sum of 3 quarters · filed 2016-03-07 | $544.00K 10-K · filed 2016-03-07 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $0.00 derived: sum of 2 quarters · filed 2015-11-13 | $544.00K 10-Q · filed 2015-11-13 | $5.03M derived: sum of 4 quarters · filed 2015-11-13 |
| 2014-06-30 | $0.00 10-Q · filed 2015-08-19 | $544.00K 10-Q · filed 2015-08-19 | $5.03M derived: sum of 3 quarters · filed 2015-10-30 | $5.03M derived: sum of 4 quarters · filed 2015-10-30 |
| 2014-03-31 | $544.00K 8-K · filed 2015-10-30 | $5.03M derived: sum of 2 quarters · filed 2015-10-30 | $5.03M derived: sum of 3 quarters · filed 2015-10-30 | |
| 2013-12-31 | $4.48M derived: 8-K 12 month − 10-Q 9 month · filed 2015-10-30 | $4.48M derived: sum of 2 quarters · filed 2015-10-30 | $5.38M 8-K · filed 2015-10-30 | |
| 2013-09-30 | $0.00 10-Q · filed 2014-11-13 | $899.00K 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |